A
Anne Kirkpatrick
Researcher at European Organisation for Research and Treatment of Cancer
Publications - 67
Citations - 8951
Anne Kirkpatrick is an academic researcher from European Organisation for Research and Treatment of Cancer. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 31, co-authored 67 publications receiving 8276 citations.
Papers
More filters
Journal ArticleDOI
Postoperative Irradiation With or Without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer
Jacques Bernier,Christian Domenge,Mahmut Ozsahin,Katarzyna Matuszewska,Jean-Louis Lefebvre,Richard H. Greiner,Jordi Giralt,Philippe Maingon,Frederic Rolland,M. Bolla,Francesco Cognetti,Jean Bourhis,Anne Kirkpatrick,Martine Van Glabbeke +13 more
TL;DR: Postoperative concurrent administration of high-dose cisplatin with radiotherapy is more efficacious than radiotherapy alone in patients with locally advanced head and neck cancer and does not cause an undue number of late complications.
Journal ArticleDOI
Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer
C. Schaake-Koning,van den Bogaert W,Otilia Dalesio,J. Festen,J. Hoogenhout,van Houtte P,Anne Kirkpatrick,Koolen M,B. Maat,A. Nijs +9 more
TL;DR: Cisplatin, given daily in combination with the radiotherapy described here to patients with nonmetastatic but inoperable non-small-cell lung cancer, improved rates of survival and control of local disease at the price of substantial side effects.
Journal ArticleDOI
Larynx Preservation in Pyriform Sinus Cancer: Preliminary Results of a European Organization for Research and Treatment of Cancer Phase III Trial
Jean-Louis Lefebvre,Dominique Chevalier,Bernard Luboinski,Anne Kirkpatrick,Laurence Collette,Tarek Sahmoud +5 more
TL;DR: Larynx preservation without jeopardizing survival appears feasible in patients with cancer of the hypopharynx in a prospective, randomized phase III study conducted by the EORTC to compare a larynx-preserving treatment with conventional treatment.
Journal ArticleDOI
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup
Robert L. Souhami,Alan W. Craft,Jan W Van der Eijken,M. Nooij,D. Spooner,Vivien H.C. Bramwell,Rafal Wierzbicki,Archibald J Malcolm,Anne Kirkpatrick,B. M. Uscinska,Martine Van Glabbeke,David Machin +11 more
TL;DR: The two-drug regimen is shorter in duration and better tolerated, and is therefore the preferred treatment, however, 5-year survival is still unsatisfactory and new approaches to treatment, such as dose intensification, are needed to improve results.
Journal ArticleDOI
A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma
E. Gortzak,A Azzarelli,J. Buesa,Vivien H.C. Bramwell,F. van Coevorden,A.N. van Geel,A. Ezzat,Armando Santoro,J.W. Oosterhuis,M. van Glabbeke,Anne Kirkpatrick,Jaap Verweij +11 more
TL;DR: The results render it less likely that major survival benefits will be achieved with neo-adjuvant chemotherapy with doxorubicin and ifosfamide in adult patients with 'high-risk' soft-tissue sarcomas.